Affecting about 400,000 people in the United States, multiple sclerosis can display an unpredictable mix of physical, cognitive and emotional symptoms that vary from person to person and can change over time. An FDA-approved medicine that targets specific B cells in the immune system, with a proven ability to slow the worsening of disability with a favorable benefit-risk profile, is now available to help in the treatment of those suffering from multiple sclerosis.
|
Archives
March 2022
Interested in Publishing on The Health IDEA?Send your query to the Publisher today! Categories
All
|